Sign in
CompletedNo phase

Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

Key facts

Who runs it
Yonsei University
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
222 people enrolled
Started
14 Aug 2020
Ended
13 Dec 2025
Type of study
Observational
Record updated
13 July 2026

Who can take part

Age
19 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Age ≥ 19 yrs
  • Severe aortic stenosis or severe aortic regurgitation
  • Agree to consent for self
  • Can follow-up for the next 2 years

Who cannot take part

  • Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
  • Pre-existing acute kidney injury
  • On ECMO or IABP
  • Life expectancy < 12 months
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

The group in the trial

  • Patients with severe aortic stenosis or severe aortic regurgitation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
13 July 2026